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Introduction: Cheilitis granulomatosa causes persistent idiopathic lip swelling and ulceration and it can sometimes
be recognized as a unique or early manifestation of Crohn’s disease. Spontaneous remission is rare and with the
lack of controlled trials, different therapeutic approaches have been used. Some cases have been treated with an
exclusion diet in the attempt to rule out diet allergens, while the most popular treatments include antibiotics such
as tetracycline and clofazimine tranilast, benzocaine topical or intralesional steroids, and cheiloplasty, with different
outcomes.
Case presentation: We describe the case of a 23-year-old Caucasian man, primarily diagnosed with cheilitis
granulomatosa for a severe lower lip swelling, and then with Crohn’s disease of the terminal ileum and anus.
Treatment of Crohn’s disease with an anti-tumor necrosis factor alpha agent (infliximab) successfully induced
remission of both the gastrointestinal disease and the oral lesion.
Conclusions: Our recommendation is that physicians should be able to recognize cheilitis granulomatosa as a
possible marker of a more complex systemic disease and proceed first with an accurate physical examination,
and further suggest investigations of the bowel. In cases of Crohn’s disease, a therapy with biological agents can
be successful.
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Cheilitis granulomatosa (CG) causes persistent idio-
pathic lip swelling and ulceration and it is included in
the orofacial granulomatosis group [1]. The pathogenesis
of this disease is still unknown. Spontaneous remission
is rare, and with the lack of controlled trials, different
therapeutic approaches have been used with regard to
the primary etiology of the CG and the personal experi-
ence of physicians. CG can occur by itself, can be due to
dietary allergens, and also be a feature of Melkersson-
Rosenthal syndrome [1]. It can sometimes be recognized
as a unique or early manifestation of Crohn’s disease, a
disease that may involve the whole gastrointestinal tract,
including the mouth and the perianal area [2], although
this is considered rare [3]. Here we describe an unusual* Correspondence: cciacci@unisa.it
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unless otherwise stated.case of a patient with ileal and perianal Crohn’s disease
associated with CG, successfully treated with infliximab.
Case presentation
We present the case of a 23-year old-Caucasian man
who was initially diagnosed with CG of the lower lip in
2009. He underwent a number of first topic and then
systemic treatments with antibiotics and steroids with
little or no improvement in the lower lip. In the same
period, he underwent psychotherapy for low self-esteem
and bad school performance due to his mouth appear-
ance. In January 2011, to confirm the diagnosis of CG, a
lower lip biopsy was taken. The pathologist described
normal keratinizing squamous epithelium overlying in-
flammatory tissue with non-caseating granulomatous in-
flammation in the deeper subcutaneous and parafollicular
tissues, consistent with cheilitis granulomatosa. His Ziehl-
Neelsen, silver, periodic acid-Schiff, and Warthin–Starry
staining results were negative for acid-fast (Mycobacteria
and Actinomyces, specifically), fungal, and spirochetal or-
ganisms. In February 2011, he complained of pain duringtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Colonoscopy. Panel A shows the rectal inflamed mucosa and panel B (arrow) the opening of an anal fistula.
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ination showed a diffuse, severe, perianal disease charac-
terized by perianal fissures, fistulae, and abscesses. After
an in-depth interview, he revealed that in 2009 he had an
over-the-counter topic preparation prescribed by his gen-
eral practitioner (GP) for anal fissuration and had had a
moderate discomfort at evacuation since then. The sever-
ity of the anal disease and the previous diagnosis of CG
alerted us to investigate the possibility of Crohn’s disease
by colonoscopy. His endoscopy examination showed a dif-
fuse aphthosis in a very limited region of the rectal am-
pulla and terminal ileum, and ileal and rectal biopsies
were suggestive of a diffuse granulomatous inflammation,
compatible with Crohn’s disease (Figure 1). Intestinal ultra-
sound and magnetic resonance of the intestine confirmed
the diagnosis of terminal ileal and perianal Crohn’s disease.
After surgical drainage of perianal disease, he was started
on infliximab (given as intravenous infusions at dosage of
5mg/kg at 0, 2 and 6 weeks, and at maintenance scheduleFigure 2 Modification of lip swelling. The figure shows gradual changes inof 5mg/kg every 8 weeks). He also underwent regular
follow-ups that included an endoscopy, histology, and in-
testinal ultrasound, as per our protocol.
Since the beginning of anti-tumor necrosis factor alpha
(TNFα) therapy in 2011, we observed a slow decrease of
the swelling of his lips as shown in Figure 2, together with
a healing of the terminal ileum assessed by endoscopies
and magnetic resonance imaging examinations. His peri-
anal lesions disappeared, although a diffuse fibrosis of the
anal canal, requiring anal dilations, is still present. No ad-
verse events were noted during the three-year therapy.
Notably, the psychological impairment improved and re-
cently he has entered into a nursing school program.
Discussion
Intestinal Crohn’s disease is accompanied by a number
of disease-specific oral lesions, such as swelling of the
lips, buccal mucosal swelling or cobble stoning, muco-
gingivitis, deep linear ulceration, perioral erythema withlip swelling in our patient since the beginning of infliximab therapy.
Table 1 Review of the most relevant literature on treatment of cheilitis granulomatosa
Author, year of publication Diagnosis Number of
cases
Therapy Results




Ruiz Villaverde and Sanchez,
2012 [15]
CG 1 Adalimumab Good
Álvarez-Garrido et al., 2011 [16] CD + CG 1 Remicade Good
Macaigne et al., 2011 [17] CD + CG 1 Remicade Good
Sasaki et al., 2011 [18] CG 1 Dental treatment Markedly
improved




Mignogna et al., 2008 [9] CD 1 TCA Good
Inui, 2008 [20] CG 1 Roxithromycin Good
Ratzinger et al., 2007 [21] CG 1 Methylprednisolone, Clofazimine Moderate
UG + CD 1 None None
MRS 1 Clofazimine Good
CG 1 Clofazimine Good
CG 1 Clofazimine None
CG 1 Clofazimine Good
MRS 1 Clofazimine Good
BG 1 Clofazimine Good
PG 1 Clofazimine Good
CG + CD 1 Methylprednisolone, Azathioprine Good
MRS 1 Methylprednisolone, Infliximab Good
CG 1 None None
CG + CD 1 Methylprednisolone, Azathioprine, Infliximab Good
PG + CD 1 Clofazimine Good
Tonkovic-Capin, 2006 [22] CD +CG 1 Methotrexate Good
Kruse-Losler et al., 2005 [23] MRS 3 Cheiloplasty Good
CG 4
Bogenrieder et al., 2003 [24] CG + CD 1 Mesalazine, Good
prednisolone per os
Hegarty et al., 2003 [25] CD + CG 5 Thalidomide Good
Sciubba et al., 2003 [26] MRS + oral granulomatosis 7 TCA chlorhexidine, Moderate
CD + CG 6 TCA, systemic sulfasalazine/steroids Moderate
Kolokotronis et al., 1997 [27] CG 5 In 3 intralesional corticosteroids Good
In 2 oral corticosteroids [2]
Ochonisky et al., 1992 [28] CD 1 Hydroxychloroquine Good
Krutchkoff and James, 1978 [29] CG 1 TCA +cheiloplasty Good
CG, cheilitis granulomatosa; CD, Crohn’s disease; TCA, triamcinolone acetate intralesional injections; UG, uranitis granulomatosa; PG, pareitis granulomatosa;
BG, blepharitis granulomatosa.
Results: none =no remission, moderate =partial remission, good =complete remission. MRS: Melkersson–Rosenthal syndrome.
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and mucosal tags [4-6]. These lesions are recurrent and
generally improve with immunosuppressant therapy in
about 70% of cases [7-10].
It is likely that in our case report Crohn’s disease was
already present in 2009 when he was first treated for anal
fissure. Concomitantly, the swelling of his lip appeared
and diagnosis of CG was made, as described in previous
reports [11]. At that time, full attention was paid to the
appearance of the mouth and his anal disease was under-
estimated. Our patient claimed that the CG, more than
the anal manifestation, caused the psychological problems
and subsequent psychotherapy, as already shown [12]. In
our case report, all the Crohn’s disease localizations were
successfully treated with infliximab. Also, the psycho-
logical impairment was overcome with the healing of his
mouth lesion.
Spontaneous remission is rare, and some cases have
been treated with an exclusion diet [13]. Table 1 summa-
rizes the most popular treatments of CG including an-
tibiotics such as tetracycline and clofazimine tranilast,
benzocaine topical or intralesional steroids, and cheilo-
plasty, with different outcomes in relation to the follow-
up period. Obviously with the lack of controlled trials,
different therapeutic approaches have been used with re-
gard to the primary etiology of the CG and the personal
experience of physicians.
Orofacial granulomatosis such as CG can be a therapeutic
challenge for gastroenterologists and other physicians.
When CG is accompanied by a major immune-medi-
ated disease, such as inflammatory bowel disease or arth-
ritis, it is reasonable to consider an anti-TNFα therapy that
will control the major disease and improve and/or heal
CG. Also, in the case of oral Crohn’s disease, cheiloplasty
has not been used so far for fear of surgery complications.Conclusions
Orofacial granulomatosis such as CG can be a therapeutic
challenge for gastroenterologists and other physicians
When CG is accompanied by a major immune-mediated
disease, such as inflammatory bowel disease or arthritis, it
is reasonable to consider an anti-TNF therapy that will
control the major disease and improve and/or heal CG.
Also, in the case of oral Crohn’s disease, cheiloplasty has
not been used so far for fear of surgery complications.
The patients may indeed psychically suffer from the
appearance of their lips, such as in our case report, and
request the maximum available therapy. Our experience
has demonstrated that infliximab is a useful therapeutic
tool for CG associated with Crohn’s disease.
Systematic assessment of the oral cavity will detect the
presence of lip swelling, ulcers of the buccal mucosa and
sulci, commissures, gingiva, tongue, floor of the mouth,and hard and soft palate and lymph nodes. If oral lesions
are present, the next step is to refer the patient to the
dentist to photograph, and if needed, take a biopsy of
the lesion for follow-up treatment.
Our recommendation is that not only the gastroenter-
ologist but also GPs, dentists and dermatologists, should
be able to recognize these lesions as possible markers of
a more complex systemic disease and proceed first with
accurate physical examination, and further suggest in-
vestigation of the bowel.
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